Japan Government Backs Earlier BOJ Rate Hike as Inflation Pressures Build 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
KOSPI Eyes Best Weekly Gain Since June as Samsung, SK Hynix Rally 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Asian Stocks Rise as AI Chip Rally Lifts South Korea, Japan 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Gold Prices Retreat From Two-Month High as Softer Inflation Eases Fed Rate Hike Bets 
France Inflation Rises 2.4% in July as Consumer Prices Increase 
European Stocks Steady as U.S.-Iran War, Euro Zone Data Keep Investors Cautious 
European Stocks Rise as U.S. Inflation Data Eases Fed Rate Hike Fears 
Wall Street Hits Record High as Softer Inflation Data Eases Fed Rate Hike Fears 
Strait of Hormuz Shipping Near Standstill After New Vessel Attacks 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Add as a preferred source on Google
Medtronic plc, a leading global healthcare technology company headquartered in Dublin, Ireland, is set to acquire EOFlow, a wearable insulin patch maker based in South Korea, for $738 million.
The Korea Economic Daily reported that Medtronic confirmed it has signed a share purchase agreement (SPA) to buy all the shares of EOFlow's chief executive officer Jesse Kim and president Luis Malave. The medical device company said that their shares are priced at KRW30,000 per share or about $22.60.
The price is said to be higher 19.8% higher compared to the KRW25,050 closing stock price on Friday, May 26. This is also said to be EOFlow's highest share price since November 2021, and the surge was hinted to be due to Medtronic's acquisition plan of the company.
EOFlow said that its CEO Jesse Kim currently owns the biggest stake in the company, and he signed a SPA with Medtronic Korea Holdings for the sale of the 18.58% stake, which he owns for KRW169.2 billion. On the other hand, EOFlow's president Luis Malave holds less than five percent of the company.
"Our goal is to simplify diabetes management and deliver the well-established benefits of automated insulin delivery to our customers in the ways they want and need," Medtronic Diabetes' executive vice president and president, Que Dallara, said in a press release. "We are excited to introduce a differentiated wearable patch option to provide more patient choice and drive further innovation for those who want to use technology to make living with diabetes easier."
EOFlow's founder and CEO, Jesse Kim, added, "We are thrilled to accelerate our next phase of growth with a partner like Medtronic who shares our goal of simplifying diabetes management to make life easier for the customers we serve."
Meanwhile, JP Morgan Securities LLC has been assigned by Medtronic as its financial advisor for the transaction, while Kim & Chang and Ropes & Gray LLP serve as its legal advisors. For EOFlow, it has hired Goldman Sachs & Co. LLC as its financial advisor and Bae, Kim & Lee LLC acting as its legal advisor.
Photo by Tony Webster/Flickr(CC BY 2.0)
